Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Global President TAVR & Surg | August 18, 2025 | August 18, 2025 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director · President, CEO | August 07, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date August 18, 2025 · Filed August 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,900.3913 |
Ending reported balance
After 2025-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-18 · Exercise / conversion · Acquired 8,950 · Balance 215,850.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Row 2 · 2025-08-18 · Sale · Disposed 8,950 · Balance 206,900.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $59.26 · Expires 2026-05-07 | Direct | 35,800 |
Reported balance
After 2025-08-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-18 · Exercise / conversion · Disposed 8,950 · Balance 35,800 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 148.1703 |
Reported balance
Holding disclosure · report date 2025-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 148.1703 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
PROCEPT BioRobotics Corp
Report date August 07, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Larry Wood Trust | 23,900 |
Reported balance
After 2026-08-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 23,900 · Balance 23,900 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 314,203 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 314,203 F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2017 Filed Dec 15, 2017 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,960 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-17-018757 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,960 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 15, 2017 Filed Dec 15, 2017 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,960 | $114.58 | $2,172,406.46 |
DisclosureSEC source: 0001225208-17-018757 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $114.23 to $115.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 15, 2017 Filed Dec 15, 2017 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,960 | $35.79 | $678,483.60 |
DisclosureSEC source: 0001225208-17-018757 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,808.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 00:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,960 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-17-017431 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,960 Underlying: Common Stock · 18,960 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 00:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,960 | $104.76 | $1,986,154.80 |
DisclosureSEC source: 0001225208-17-017431 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $104.15 to $105.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 00:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,960 | $35.79 | $678,483.60 |
DisclosureSEC source: 0001225208-17-017431 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,808.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 16, 2017 Filed Oct 16, 2017 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,960 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-17-016297 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,920 Underlying: Common Stock · 18,960 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 16, 2017 Filed Oct 16, 2017 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,960 | $108.54 | $2,057,901.34 |
DisclosureSEC source: 0001225208-17-016297 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $108.13 to $109.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 16, 2017 Filed Oct 16, 2017 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,960 | $35.79 | $678,483.60 |
DisclosureSEC source: 0001225208-17-016297 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,808.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 21:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,960 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-17-015095 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,880 Underlying: Common Stock · 18,960 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 21:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,447 | $112.79 | $1,178,295.19 |
DisclosureSEC source: 0001225208-17-015095 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $112.66 to $112.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 21:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,513 | $112.32 | $956,150.36 |
DisclosureSEC source: 0001225208-17-015095 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,295.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $111.66 to $112.64. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 21:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,960 | $35.79 | $678,483.60 |
DisclosureSEC source: 0001225208-17-015095 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,808.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 18,960 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-17-014420 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,840 Underlying: Common Stock · 18,960 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,960 | $111.81 | $2,119,965.00 |
DisclosureSEC source: 0001225208-17-014420 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $111.57 to $112.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 30, 2017 Filed Aug 30, 2017 21:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 18,960 | $35.79 | $678,483.60 |
DisclosureSEC source: 0001225208-17-014420 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,808.4338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 31, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| July 10, 2017 Filed Jul 11, 2017 21:41 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 592 | $118.17 | $69,956.64 |
DisclosureSEC source: 0001225208-17-012563 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,848.4338 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009795 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,625 Underlying: Common Stock · 3,625 shares Expires not disclosed F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 25,600 | $0.00 Strike: $110.25 | $0.00 |
DisclosureSEC source: 0001225208-17-009795 · doc4.xml · derivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2024-05-10 F4 · derivative.exercise_date: These options were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 11, 2017 Filed May 15, 2017 21:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009795 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,372.6731 F1 · shares: These restricted stock units were granted on May 11, 2017 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009635 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2017-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F4 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 5,154 | $110.58 | $569,929.32 |
DisclosureSEC source: 0001225208-17-009635 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,472.6731 F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009635 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,626.6731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F1 · price: On May 8, 2014, the Reporting Person was granted a target number of shares (6,000) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 10, 2017, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,258 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-042551 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,258 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,758 | $81.71 | $879,036.18 |
DisclosureSEC source: 0001225208-16-042551 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,943.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $81.22 to $82.17. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $82.47 | $206,177.00 |
DisclosureSEC source: 0001225208-16-042551 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,701.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $82.22 to $82.94. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 00:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,258 | $44.62 | $591,505.67 |
DisclosureSEC source: 0001225208-16-042551 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,201.7564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,257 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-041101 · doc4.xml · derivative · entry 7 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,258 Underlying: Common Stock · 13,257 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,457 | $92.07 | $502,436.36 |
DisclosureSEC source: 0001225208-16-041101 · doc4.xml · nonDerivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,943.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F6 · price: This transaction was executed in multiple trades at prices ranging from $91.60 to $92.54. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,000 | $93.23 | $279,675.90 |
DisclosureSEC source: 0001225208-16-041101 · doc4.xml · nonDerivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,400.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $92.71 to $93.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,700 | $94.20 | $254,331.63 |
DisclosureSEC source: 0001225208-16-041101 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,400.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $93.80 to $94.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,100 | $95.25 | $200,034.45 |
DisclosureSEC source: 0001225208-16-041101 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,100.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $94.81 to $95.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,257 | $44.62 | $591,461.06 |
DisclosureSEC source: 0001225208-16-041101 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,200.7564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,257 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-040164 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,515 Underlying: Common Stock · 13,257 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,841 | $119.25 | $1,531,335.48 |
DisclosureSEC source: 0001225208-16-040164 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,943.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $118.70 to $119.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 416 | $119.85 | $49,858.68 |
DisclosureSEC source: 0001225208-16-040164 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,784.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $119.73 to $119.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,257 | $44.62 | $591,461.06 |
DisclosureSEC source: 0001225208-16-040164 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,200.7564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,257 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-16-038851 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,772 Underlying: Common Stock · 13,257 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,742 | $115.20 | $1,352,624.39 |
DisclosureSEC source: 0001225208-16-038851 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,943.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.60 to $115.58. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,515 | $115.81 | $175,454.57 |
DisclosureSEC source: 0001225208-16-038851 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,685.7564 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $115.71 to $15.985. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,257 | $44.62 | $591,461.06 |
DisclosureSEC source: 0001225208-16-038851 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, THV Replacement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,200.7564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.